Quince Therapeutics, Inc. QNCX

Rank #2254 · Nasdaq · $0.3B market cap

⚠ Going-concern flag — the auditor (BDO USA, P.C.) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

27.2

P/E

-5.0

P/B

3.36

ROE

-66.8%

Op. Margin

–%

Debt Ratio

99%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -5.0x, P/B 3.36x. Ranks in the top 72% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -66.8%. Ranks in the top 91% of the universe.

Safety ★★★☆☆

Good

Debt ratio 99%. Ranks in the top 39% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2019	–	$-0.0B	$-0.0B	$-0.0B	–	-7
2020	–	$-0.0B	$-0.0B	$-0.0B	–	-44
2021	–	$-0.0B	$-0.0B	$-0.0B	–	-53
2022	–	$-0.1B	$-0.1B	$0.2B	–	8
2023	–	$-0.1B	$-0.1B	$0.1B	–	3
2024	–	$-0.0B	$-0.0B	$0.1B	–	82
2025	–	$-0.1B	$-0.1B	$0.1B	–	99

← See the full screener